Rezpegaldesleukin

SAN FRANCISCO, July 29, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of severe-to-very severe alopecia areata (AA) in adults and pediatric patients 12 years of age and older who weigh at least 40 kilograms. Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body to stimulate proliferation of inhibitory immune cells known as regulatory T cells (Tregs). Results from multiple clinical trials showed that rezpegaldesleukin safely and dose-dependently increased Tregs.1 "We are pleased that rezpegaldesleukin has been granted Fast Track designation for the treatment of alopecia areata, adding to its Fast Track designation in atopic dermatitis," said Jonathan Zalevsky, Ph.D., Senior Vice President and Chief Research & Development Officer at Nektar. "Alopecia areata is a chronic, systemic, immune-mediated inflammatory disease, and there is an urgent need for novel mechanistic approaches that could treat the underlying pathogenesis of this disorder. We remain on track to announce topline data in December from our ongoing REZOLVE-AA Phase 2b study for rezpegaldesleukin in alopecia areata, and we look forward to the opportunity to collaborate quickly with the agency on a potential registrational program following the completion of Phase 2." The goal of the FDA's Fast Track process is to ensure that important new treatments reach patients as quickly as possible. The designation is granted to investigational therapies that treat serious conditions and have the potential to address an unmet medical need. A drug candidate that receives Fast Track designation is eligible for more frequent meetings and written interactions with the FDA to discuss the drug candidate's development plan as well as possible eligibility for rolling review and priority review. About REZOLVE-AA The REZOLVE-AA (NCT06340360) study enrolled approximately 90 patients with severe-to-very severe alopecia areata who have not previously been treated with a JAK inhibitor or other biologic. Patients were randomized across two different dose regimens of rezpegaldesleukin or placebo. The primary efficacy endpoint will evaluate the mean percent change in the Severity of Alopecia Tool (SALT) score at the end of the 36-week induction period. Secondary endpoints include the proportion of participants with greater than or equal to 50% reduction in SALT score at week 36 and other assessed timepoints, the mean percent improvement in SALT score at other assessed timepoints, and the proportion of patients achieving SALT-20 (an absolute SALT score of less than or equal to 20). The Company expects to share these results in December 2025. This trial was initiated in March 2024. Patients were enrolled across approximately 30 sites globally with: 62% enrolled in Poland; 24% enrolled in Canada; and 14% enrolled in the United States. Enrollment criteria in the study included a diagnosis of severe-to-very severe alopecia areata (≥ 50% scalp involvement) as measured using the SALT score at both screening and randomization. Patients who experienced an unstable course of alopecia areata over the last 6 months per investigator assessment were excluded from the study. Patients with diffuse alopecia and other forms of alopecia were also excluded. Patient randomization was stratified based on baseline disease severity as measured by the SALT score. About Rezpegaldesleukin Autoimmune and inflammatory diseases cause the immune system to mistakenly attack and damage healthy cells in a person's body. A failure of the body's self-tolerance mechanisms enables the formation of the pathogenic T lymphocytes that conduct this attack. Rezpegaldesleukin is a potential first-in-class resolution therapeutic that may address this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. It targets the interleukin-2 receptor complex in the body to stimulate proliferation of powerful inhibitory immune cells known as regulatory T cells. By activating these cells, rezpegaldesleukin may act to bring the immune system back into balance. In February 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older who weigh at least 40 kilograms with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Rezpegaldesleukin is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases. It is wholly owned by Nektar Therapeutics. About Alopecia Areata Alopecia areata is a disease where a patient's own immune system attacks hair follicles resulting in hair loss.2 The lifetime incidence of alopecia areata is 2% in both men and women.2 Nearly 6.7 million people in the U.S. and 160 million worldwide develop alopecia areata in their lifetime. About 700,000 people in the U.S. currently have some form of alopecia areata.3 It is often associated with other auto-immune conditions as well as depression and anxiety.2 The disease has a tremendous impact on quality of life for patients.4 Available therapies for alopecia are not durable and have high relapse rates and there is an urgent unmet medical need for novel, more effective therapies for patients. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit and follow us on LinkedIn. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements which can be identified by words such as: "will," "could," "forward," "expect," "develop," "potential," "plan," and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding the therapeutic potential and safety profile of, and future development plans for, rezpegaldesleukin, the results and timing for reporting data from REZOLVE-AA, the potential for rezpegaldesleukin to be a first-in-class T regulatory cell therapy, the potential market opportunity in atopic dermatitis and alopecia areata, the advantage of a broad-based Treg mechanism over other immune-modulation approaches in development, and the high unmet need for a new mechanism of action in alopecia areata. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential of rezpegaldesleukin are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin is an investigational agent and continued research and development for this drug candidate is subject to substantial risks, including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iii) rezpegaldesleukin is in clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval; (iv) the timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (v) a Fast Track designation does not increase the likelihood that rezpegaldesleukin will receive marketing approval in the United States; (vi) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vii) certain other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2025. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. For Investors: Corey Davis, Ph.D. LifeSci Advisors, LLC [email protected] 212-915-2577 For Media: Madelin Hawtin LifeSci Communications [email protected] 603-714-2638 SOURCE Nektar Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

礼来口服减肥药Orforglipron的III期顶线数据即将揭晓今年第三季度，礼来计划公布III期ATTAIN试验的顶线结果，该研究旨在评估Orforglipron在肥胖或超重并伴有体重相关合并症的成人中的减重潜力。目前来看市场对Orforglipron的期待值已然拉满。今年4月，礼来公布的2型糖尿病III期数据显示，40周时药物将血糖水平降低1.5%；尽管研究并非以减重为主要终点，但患者平均体重仍下降了7.9%，而安慰剂组仅下降1.6%。BMO资本市场更是直言Orforglipron已兑现礼来所承诺的“让口服药达到注射剂型疗效”的豪言。Scholar Rock静待Apitegromab花开去年10月公布的III期数据显示，2–12岁患者在Hammersmith运动功能量表扩展版（HFMSE）上较安慰剂平均提升1.8分（公司称该量表是衡量SMA运动功能的“金标准”）。Apitegromab一旦获批，不仅将在SMA市场站稳脚跟，还可能为“减肥药联合肌肉保留”这一全新策略背书。上月公布的II期数据显示，与礼来减重药Zepbound（tirzepatide）联用时，Apitegromab可多保留55%的肌肉体重。罕见病赛道未来半年内将迎来两项关键审批Regenxbio：一次性基因疗法Regenxbio递交的基因疗法clemidsogenelanparvovec旨在“一针治愈”。I/II/III期汇总数据显示，脑脊液生物标志物DS26水平骤降86%，直接反映中枢神经系统病变活动度显著降低。FDA预计将在11月9日前给出答复。Denali：穿越血脑屏障的酶替代疗法Denali Therapeutics的tividenofuspalfa则采用可穿越血脑屏障的酶替代策略。今年2月公布的I/II期数据表明，该药不仅带来“重大和显著”的生物标志物改善，还同步提升听力和发育指标。4月公司启动滚动BLA，5月完成递交；前不久，宣布FDA已将目标审批日定为2026年1月5日。Atai Life Sciences即将迎来精神分裂症IIb期数据在难治性抑郁症领域初露锋芒后Atai Life Sciences把目光投向了更高的读数：其口服型神经调质RL-007针对“精神分裂症相关认知损害”（CIAS）的IIb期顶线数据预计将在2025年第三季度公布。据公司路演材料，认知障碍是精神分裂症的“核心症状”，全球约有1800万患者受此困扰，目前尚无获批疗法。RL-007通过多通路神经调节发挥作用，早期研究显示出可重复的认知获益：其IIa期结果显示，药物呈剂量依赖性改善标准化认知评分；脑电图也捕捉到警觉性指标的显著提升。Atai迄今已在500余名受试者中评估RL-007，安全性与耐受性表现良好并且未见药物相关严重不良事件，且药物联用的相互作用风险“极低”，使其有望作为现有标准治疗的增量联用方案。Nektar的rezpegNektar Therapeutics的T细胞激活剂rezpegaldesleukin（rezpeg）的IIb期数据即将在第四季度揭晓。作用机制上，rezpeg通过靶向IL-2受体从而选择性扩增调节性T细胞（Treg），同时避免激活致病的CD8⁺和CD4⁺毒性T细胞，从而“踩刹车”而非“踩油门”式地抑制自身免疫。Nektar计划将rezpeg用于多种免疫-炎症性疾病。今年2月，公司宣布IIb期REZOLVE-AA研究完成入组，受试者为未使用JAK抑制剂或其他生物制剂的重度至极重度斑秃患者。除斑秃外，rezpeg还在1型糖尿病与特应性皮炎中进行探索。参考资料1.https://www.biospace.com/drug-development/5-second-half-biopharma-milestones-to-watch转载自会会药咖免责声明本文系转载，仅做分享之用，不代表平台观点。图片、文章、字体等版权均属于原作者所有，如有侵权请告知，我们会及时处理。艾美达医药咨询艾美达（北京）医药信息咨询有限公司，成立于2014年4月，是一家专业的医药行业咨询服务提供商。公司致力于将产业政策研究与真实世界的数据挖掘深度结合，洞悉行业政策对市场的影响，通过专业的研究提供前瞻性的市场分析，为企业产品上市后的市场准入提供整体解决方案。